Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$55.47 USD

55.47
3,077,855

-0.07 (-0.13%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote

The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

Smart Beta ETF report for FVD

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up

Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.

SNY or LLY: Which Is the Better Value Stock Right Now?

SNY vs. LLY: Which Stock Is the Better Value Option?

Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?

Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Kinjel Shah headshot

Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study

Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.

Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised

Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong

Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales

Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.

Is a Surprise Coming for Sanofi (SNY) This Earnings Season?

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View

Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.

AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.

Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?

Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.

Ekta Bagri headshot

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.